Lycia Sets IPO Terms to Finance Clinical LYTAC Proof-of-Concept
Lycia Therapeutics filed terms for a proposed US initial public offering of 14.7 million shares at $16–$18 per share. At the $17 midpoint, the offering would raise approximately $249.9 million gross and an estimated…
